Alloksys’s RESCAP® platform therapeutic compound will be applied in patients that suffer from severe burn trauma. RESCAP® administration is expected to significantly attenuate the overall ischemic clinical condition of these severely burn-patients and thereby improve on recuperation of these patients, primarily during ICU treatment period. The study will be carried out at the Burn Centre, Red Cross Hospital, Beverwijk, The Netherlands, lead by dr P.M. van Zuijlen
Alloksys reports interim results of its clinical phase IIb trial with Alkaline Phosphatase therapy RESCAP® in critical care patients
www.alloksys.com Wageningen, the Netherlands, 24 August 2023 – Alloksys Life Sciences, a clinical stage biotech company specializing in the development of critical care medicines, today
